PC

Philip Cohen

For 45 years, Prof. Cohen has studied protein phosphorylation in cell regulation and human disease, and has made multiple major contributions to the field. He is now working to unravel signaling networks within the innate immune system involving protein ubiquitylation and phosphorylation during bacterial and viral infections. Prof Cohen is also involved in commercial activities based in Dundee and is frequently cited as the magnet for academics and biotechnology companies and economic regeneration in the city, as 15% of the Dundee economy derives from biotech and its employees.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


MISSION Therapeutics

MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).


Employees

11-50

Links